Table S2.
Distribution of treatment by cluster
| Treatment (% of patients) | Total N=3255 |
Cluster 1 (less obstruction) n=1310 |
Cluster 2 (less obstruction, psychoanaleptic users, high comorbidity) n=238 |
Cluster 3 (greater obstruction, no pneumonia history) n=1189 |
Cluster 4 (greater obstruction, high comorbidity, pneumonia history) n=374 |
Cluster 5 (greater obstruction, low BMI) n=144 |
|---|---|---|---|---|---|---|
| VI 25 | 25.1 | 24.7 | 23.5 | 26.6 | 23.3 | 25.0 |
| FF/VI 50/25 | 25.2 | 24.7 | 27.3 | 23.5 | 30.5 | 26.4 |
| FF/VI 100/25 | 24.8 | 25.7 | 25.6 | 24.6 | 24.3 | 17.4 |
| FF/VI 200/25 | 24.9 | 25.0 | 23.5 | 25.3 | 22.0 | 31.3 |
Abbreviations: BMI, body mass index; FF/VI, fluticasone furoate/vilanterol; VI, vilanterol.